Kamada Ltd. (KMDA) Rating Lowered to Sell at Zacks Investment Research

Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

KMDA has been the topic of a number of other research reports. ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Finally, TheStreet cut shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $8.50.

Shares of Kamada (KMDA) opened at 4.85 on Tuesday. The company has a 50 day moving average of $4.61 and a 200 day moving average of $5.97. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The company’s market cap is $181.39 million.

Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm’s revenue was up 70.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) EPS. On average, analysts expect that Kamada will post $0.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/10/kamada-ltd-kmda-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of large investors have recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. raised its position in Kamada by 10.5% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the period. Vanguard Group Inc. raised its position in Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the period. Renaissance Technologies LLC raised its position in Kamada by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after purchasing an additional 37,800 shares during the period. Navellier & Associates Inc purchased a new position in Kamada in the 2nd quarter worth $303,000. Finally, Paulson & CO. Inc. raised its position in Kamada by 8.2% in the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after purchasing an additional 60,000 shares during the period. Institutional investors own 7.29% of the company’s stock.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of th

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

KMDA has been the topic of a number of other research reports. ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Finally, TheStreet cut shares of Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $8.50.

Shares of Kamada (KMDA) opened at 4.85 on Tuesday. The company has a 50 day moving average of $4.61 and a 200 day moving average of $5.97. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The company’s market cap is $181.39 million.

Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The firm’s revenue was up 70.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) EPS. On average, analysts expect that Kamada will post $0.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2017/10/10/kamada-ltd-kmda-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of large investors have recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. raised its position in Kamada by 10.5% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,000 shares during the period. Vanguard Group Inc. raised its position in Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the period. Renaissance Technologies LLC raised its position in Kamada by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after purchasing an additional 37,800 shares during the period. Navellier & Associates Inc purchased a new position in Kamada in the 2nd quarter worth $303,000. Finally, Paulson & CO. Inc. raised its position in Kamada by 8.2% in the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after purchasing an additional 60,000 shares during the period. Institutional investors own 7.29% of the company’s stock.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply